| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |